DOCSLIB.ORG

Services and Capabilities Deep Dive: Psychiatry Download

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Services and Capabilities Deep Dive: Psychiatry Download DEEP DIVE A DEEPER DIVE INTO PSYCHIATRY AN INTEGRATED ADVANTAGE As a full-service and therapeutically-focused CRO, Medpace specializes in the design and conduct of global trials in neuroscience clinical research, including psychiatry. We bring a global footprint, strategic medical, regulatory, and operational leadership as well as fully integrated Central Labs and Core Imaging services to accelerate psychiatric studies. • Highly relevant operational know-how and subject matter expertise in psychiatry and neurology drug development • A well-profiled network of investigative sites enables timely enrollment and high-quality conduct of trials • A team of Clinical Research Associates and Clinical Trial Managers experienced in psychiatric research • Integrated imaging and central laboratory services, ensuring seamless logistics, review, and testing THERAPEUTICALLY-FOCUSED TEAM Medpace is unique in its scientifically-driven approach to clinical research. Our model gives Sponsors the advantage of early and ongoing insight and guidance Accelerate your psychiatric studies from a team of therapeutic experts throughout the with Medpace’s full-service team trial design and execution. Our highly experienced of medical and regulatory experts, team of medical, regulatory, and operational experts highly-experienced clinical trial work collaboratively to conduct clinical trials. We understand issues from the perspectives of management teams, central labs, Sponsors, clinical investigators, scientific leaders, and and core imaging labs. reviewers at regulatory agencies. With this insight, we successfully define and execute clear development plans from beginning to end. NEUROLOGY AND PSYCHIATRY Page 1 of 6 EXPERTS Sarah DeRossett, MD, PhD Senior Medical Director, Medical Department, Neurology, Psychopharmacology, Analgesia EXPERT INSIGHT Dr. Sarah DeRossett is a board-certified neurologist Serving as therapeutic team leaders, our in-house with 15 years of experience in clinical and academic medical doctors apply years of psychiatric drug neurology, plus more than 10 years of drug development experience to each study. Our medical development experience. leaders provide strategic direction for study design and planning, train operational staff, work with Experience Summary Investigators, provide medical monitoring, and • Drug development expertise in neuropsychiatric meet with regulatory agencies as well as our global disorders, dementia, opioid use disorder, sleep, regulatory affairs experts to provide strategic guidance and other CNS disorders into the best pathways to accelerate approvals. • Clinical and drug development experience in Medpace MDs are embedded throughout every study, pain and analgesia providing greater depth of expertise and the ability to • Extensive research experience in tackle complex and challenging diseases. psychopharmacology with special focus on opioids • Leadership of clinical development programs in Parkinson’s disease, Alzheimer’s disease, Migraine, Restless Leg Syndrome (RLS), Neuropathic pain, Epilepsy, and Opioid Use Disorder • Broad experience in pharmaceutical R&D, Sarah DeRossett, MD, PhD Toshihiro Hokonohara, MD Richard D. Scheyer, MD Senior Medical Director, Medical Director, Vice President, including single point of accountability for Medical Department Medical Department Medical Department clinical development plans, medical governance, and support of regulatory submissions • Well-published in the peer-reviewed medical and scientific literature Education Summary • Doctor of Medicine, cum laude, Emory Thomas R. Thompson, MD James Vornov, MD, PhD Vice President, Vice President, University School of Medicine Medical Department Medical Department • Postdoctoral Fellowship, Pharmacology, Emory University School of Medicine • Residency in Neurology, The Johns Hopkins Hospital NEUROLOGY AND PSYCHIATRY Page 2 of 6 Toshihiro Hokonohara, MD Thomas R. Thompson, MD Medical Director, Medical Department, Vice President, Medical Department, Neurology, Psychiatry Neurology, Psychiatry Dr. Toshihiro Hokonohara is a board-certified Dr. Thompson is board certified in both Psychiatry and neurologist with over 15 years of clinical practice and Geriatric Psychiatry and has over 20 years of phases academic neurology including experience in leadership I-IV clinical development experience. roles at pharmaceutical and global contract research organizations. Experience Summary • Experience in numerous indications including Experience Summary major depression, substance use disorders, • Drug development expertise in neuropsychiatric bipolar disorders, schizophrenia, anxiety disorders, dementia, autoimmune disease, disorders, Parkinson's disease, dementia, oncology and other CNS and Internal Medicine epilepsy, headache and pain disease • Industry leadership roles with responsibility • Clinical and drug development experience in for clinical development plans, medical affairs, neuro-immunological disease regulatory submissions, medical governance, • Extensive research experience in some and medical monitoring neurological hereditary disease • Leadership and single point of accountability • Pharmacovigilance Leader of clinical for numerous programs as a previous Director development programs in Epilepsy of Neurosciences and Clinical Development for • Broad experience in pharmacovigilance medical 12 years at a large pharmaceutical company governance and support of regulatory • Well-published in the peer-reviewed medical submissions and scientific literature Education Summary Education Summary • Doctor of Medicine, Kyushu University – • Bachelor of Science, Biology, University of Fukuoka, Japan Central Florida • Residency in Neurology, Kyushu University • Doctor of Medicine, Temple University, School Hospital – Fukuoka, Japan of Medicine • Diplomate, American Board of Neurology and Psychiatry • Residency in Psychiatry, Emory University School of Medicine • Fellowship in Geriatric, Emory University School of Medicine NEUROLOGY AND PSYCHIATRY Page 3 of 6 Richard D. Scheyer, MD James Vornov, MD, PhD Vice President, Medical Department, Vice President, Medical Department, Neurology, Pharmacology Neurology, Analgesia, Psychiatry Dr. Richard Scheyer is a board-certified neurologist Dr. James Vornov is a board-certified neurologist with with over 30 years of professional medical experience over 18 years of director level clinical development which includes 18 years dedicated to clinical experience. drug development. Experience Summary Experience Summary • Brought multiple compounds into first-in- • Pioneer in translational medicine and Phase I/IIa man to proof-of-concept and successful drug development with special interest in early NDA submission. Provided broad clinical trial demonstration of clinical efficacy design expertise, clinical pharmacology • Led a team that designed and executed an early experience, operational excellence and global development program for next-generation regulatory strategy development across a alpha-2 delta ligand, including capsaicin broad range of CNS diagnostics and challenge, and crafting Proof of Concept therapeutics strategy for novel ion channel blockers • Expertise in the rapid transition of compounds • Highly-regarded author with over 60 from the laboratory to clinical proof of concept manuscripts and abstracts, with a focus on using Critical Path technologies such as clinical pharmacology and therapeutic activity in biomarkers, PK/PD modeling and clinical trial areas ranging from diabetes to oncology simulation • Launched first controlled trial natural product- • Worked in multiple CNS therapeutic areas derived protein kinase C activator in Alzheimer’s having directed programs in Depression, at previous company Suicidal Ideation, Parkinson’s disease treatment and diagnosis, stroke, neuropathic Education Summary pain, diabetic and chemotherapy-induced • Bachelor of Science, Physics, Stanford University peripheral neuropathies, anesthesia and • Doctor of Medicine, The State Universityof New York, Upstate Medical University brain tumors • Residency in Neurology, Yale University Education Summary • Fellowship Training in Epilepsy, Yale University • Bachelor of Arts, Biology & Psychology, Columbia University • Doctor of Medicine, Emory University, School of Medicine • Doctor of Philosophy, Anatomy, Emory University, School of Medicine NEUROLOGY AND PSYCHIATRY Page 4 of 6 EXPERIENCE Developing effective treatments for psychiatric disorders such as depression, bipolar disorder, anxiety disorders, and schizophrenia requires unique expertise. Medpace medical, regulatory, and operational experts bring a broad range of experience in designing and conducting psychiatric studies for psychiatric clinical development across adult, geriatric, and pediatric populations. Indication expertise: • Addictive Disorders • Anxiety Disorders • Attention-Deficit/Hyperactivity Disorder • Bipolar Disorder • Cognition Disorders • Depression • Developmental Disorders • Eating Disorders • Schizophrenia • Sleep Disorders • Neuropsychiatric Disorders RECRUITMENT AND SITE RELATIONSHIPS With broad neuroscience experience and relationships with Investigators and Key Opinion Leaders (KOLs) worldwide, we can select the best sites for your specific program. We provide in-depth knowledge of screening tools and rating scales and will provide oversight for rater services including subjective assessments, inter- rater reliability, and scale validation. SPECIALIZED MEDICAL DEVICE EXPERTISE There is a growing number of neurologic and psychiatric
Load more

Recommended publications
  • Autism Practice Parameters
    American Academy of Child and Adolescent Psychiatry AACAP is pleased to offer Practice Parameters as soon as they are approved by the AACAP Council, but prior to their publication in the Journal of the American Academy of Child and Adolescent Psychiatry (JAACAP). This article may be revised during the JAACAP copyediting, author query, and proof reading processes. Any final changes in the document will be made at the time of print publication and will be reflected in the final electronic version of the Practice Parameter. AACAP and JAACAP, and its respective employees, are not responsible or liable for the use of any such inaccurate or misleading data, opinion, or information contained in this iteration of this Practice Parameter. PRACTICE PARAMETER FOR THE ASSESSMENT AND TREATMENT OF CHILDREN AND ADOLESCENTS WITH AUTISM SPECTRUM DISORDER ABSTRACT Autism spectrum disorder (ASD) is characterized by patterns of delay and deviance in the development of social, communicative, and cognitive skills which arise in the first years of life. Although frequently associated with intellectual disability, this condition is distinctive in terms of its course, impact, and treatment. ASD has a wide range of syndrome expression and its management presents particular challenges for clinicians. Individuals with an ASD can present for clinical care at any point in development. The multiple developmental and behavioral problems associated with this condition necessitate multidisciplinary care, coordination of services, and advocacy for individuals and their families. Early, sustained intervention and the use of multiple treatment modalities are indicated. Key Words: autism, practice parameters, guidelines, developmental disorders, pervasive developmental disorders. ATTRIBUTION This parameter was developed by Fred Volkmar, M.D., Matthew Siegel, M.D., Marc Woodbury-Smith, M.D., Bryan King, M.D., James McCracken, M.D., Matthew State, M.D., Ph.D.
    [Show full text]
  • Specificity of Psychosis, Mania and Major Depression in A
    Molecular Psychiatry (2014) 19, 209–213 & 2014 Macmillan Publishers Limited All rights reserved 1359-4184/14 www.nature.com/mp ORIGINAL ARTICLE Specificity of psychosis, mania and major depression in a contemporary family study CL Vandeleur1, KR Merikangas2, M-PF Strippoli1, E Castelao1 and M Preisig1 There has been increasing attention to the subgroups of mood disorders and their boundaries with other mental disorders, particularly psychoses. The goals of the present paper were (1) to assess the familial aggregation and co-aggregation patterns of the full spectrum of mood disorders (that is, bipolar, schizoaffective (SAF), major depression) based on contemporary diagnostic criteria; and (2) to evaluate the familial specificity of the major subgroups of mood disorders, including psychotic, manic and major depressive episodes (MDEs). The sample included 293 patients with a lifetime diagnosis of SAF disorder, bipolar disorder and major depressive disorder (MDD), 110 orthopedic controls, and 1734 adult first-degree relatives. The diagnostic assignment was based on all available information, including direct diagnostic interviews, family history reports and medical records. Our findings revealed specificity of the familial aggregation of psychosis (odds ratio (OR) ¼ 2.9, confidence interval (CI): 1.1–7.7), mania (OR ¼ 6.4, CI: 2.2–18.7) and MDEs (OR ¼ 2.0, CI: 1.5–2.7) but not hypomania (OR ¼ 1.3, CI: 0.5–3.6). There was no evidence for cross-transmission of mania and MDEs (OR ¼ .7, CI:.5–1.1), psychosis and mania (OR ¼ 1.0, CI:.4–2.7) or psychosis and MDEs (OR ¼ 1.0, CI:.7–1.4).
    [Show full text]
  • 2021 Psychiatry CERT Content Specifications
    CERTIFICATION EXAMINATION IN PSYCHIATRY Beginning in 2017, the American Board of Psychiatry and Neurology, Inc. (ABPN) issued two- dimensional content specifications for the psychiatry, neurology and child neurology certification examinations. Questions for the September 2021 psychiatry, neurology and child neurology certification examinations will conform to these content specifications. Within the two-dimensional format, one dimension is comprised of disorders and topics while the other is comprised of competencies and mechanisms that cut across the various disorders of the first dimension. By design, the two dimensions are interrelated and not independent of each other. All of the questions on the examination will fall into one of the disorders/topics and will be aligned with a competency/mechanism. For example, an item on substance use could focus on treatment, or it could focus on systems-based practice. The psychiatry, neurology and child neurology content specifications can be accessed from the specialty certification section of our website. Candidates should use the detailed content specifications as a guide to prepare for a certification examination. Scores for these examinations will be reported in a standardized format rather than the previous percent correct format. Starting in 2018, all future examinations given by the ABPN will gradually conform to the two- dimensional content specification. The American Board of Psychiatry and Neurology, Inc. is a not-for-profit corporation dedicated to serving the public interest and the professions of psychiatry and neurology by promoting excellence in practice through certification and continuing certification processes. For more information, please contact us at [email protected] or visit our website at www.abpn.com.
    [Show full text]
  • Comorbid Psychiatric Disorders in Children with Autism: Interview Development and Rates of Disorders
    J Autism Dev Disord (2006) 36:849–861 DOI 10.1007/s10803-006-0123-0 ORIGINAL PAPER Comorbid Psychiatric Disorders in Children with Autism: Interview Development and Rates of Disorders Ovsanna T. Leyfer Æ Susan E. Folstein Æ Susan Bacalman Æ Naomi O. Davis Æ Elena Dinh Æ Jubel Morgan Æ Helen Tager-Flusberg Æ Janet E. Lainhart Published online: 15 July 2006 Ó Springer Science+Business Media, Inc. 2006 Abstract The Kiddie Schedule for Affective Disorders sample demonstrated a high prevalence of specific phobia, and Schizophrenia was modified for use in children and obsessive compulsive disorder, and ADHD. The rates of adolescents with autism by developing additional screening psychiatric disorder in autism are high and are associated questions and coding options that reflect the presentation of with functional impairment. psychiatric disorders in autism spectrum disorders. The modified instrument, the Autism Comorbidity Interview- Keywords Psychopathology Æ Autism Æ Psychiatric Present and Lifetime Version (ACI-PL), was piloted and interview Æ Comorbidity frequently diagnosed disorders, depression, ADHD, and OCD, were tested for reliability and validity. The ACI-PL provides reliable DSM diagnoses that are valid based on clinical psychiatric diagnosis and treatment history. The Children with autism frequently have problematic emo- tional reactions and behaviors along with the features that O. T. Leyfer Department of Psychological and Brain Sciences, University define autism. Disturbances of emotion, attention, activity, of Louisville, Louisville, KY, USA and thought, and associated behavioral problems occur in children with autism of all ages (Lainhart, 1999). It is not S. E. Folstein yet known how often these additional difficulties are due to Department of Psychiatry, Johns Hopkins University, Baltimore, MD, USA comorbid psychiatric disorders.
    [Show full text]
  • First-Episode Psychosis: a Clinical Approach
    J Am Board Fam Pract: first published as 10.3122/15572625-13-6-430 on 1 November 2000. Downloaded from First-Episode Psychosis: A Clinical Approach S. Charles Schulz, MD, Deanna Bass, MD, and Cynthia S. Vrabel, MD Background: Psychotic illnesses, such as schizophrenia and bipolar illness, are relatively common and clearly devastating diseases. Most scientific literature focuses on research and care of patients suffering from psychotic illnesses in the middle age-group; subsequently, the first episode or early stages of psy­ chotic illnesses have been relatively ignored, especially the issues of early diagnosis and inten-ention. The purpose of this article is to highlight issues of first-episode schizophrenia for the family physician and to discuss (1) diagnosis, (2) neuropsychiatry research, (3) new medications, and (4) family issues. Methods: To approach the issues of first-episode schizophrenia, we describe a case of a young woman who suffered her first episode of psychosis. Relevant literature related to the early stages of psychosis, including new pharmacologic treatments, is addressed. Results: This report of our patient, a 19-year-old woman, illustrates the problems of a long prodro­ mal phase of her illness, the use of medications that might have worsened her condition, and the suc­ cessful use of new antipsychotic medications. Her family's issues as the patient went through this phase of her illness and recovery are reviewed. Conclusions: Patients at the outset of a psychotic illness are frequently first seen by a family physi­ cian. Familiarity with current diagnostic criteria and effectiveness of new treatments can lead to im­ proved detection and overall outcome.
    [Show full text]
  • Workbook Psychiatry and Narcology
    Kharkiv National Medical University Department of Psychiatry, Narcology and Medical Psychology WORKBOOK MANUAL FOR INDIVIDUAL WORK FOR MEDICAL STUDENTS PSYCHIATRY AND NARCOLOGY (Part 2) Student ___________________________________________________________ Faculty _________________________________________________________ Course _________________ Group _____________________________________ Kharkiv 2019 Затверджено вченою радою ХНМУ Протокол №5 від 23.05.2019 р. Psychiatry (Part 2) : workbook manual for individual work of students / I. Strelnikova, G. Samardacova, К. Zelenska – Kharkiv, 2019. – 103 p. Копіювання для розповсюдження в будь-якому вигляді частин або повністю можливо тільки з дозволу авторів навчального посібника. CLASS 7. NEUROTIC DISORDERS. CLINICAL FORMS. TREATMENT AND REHABILITATION. POSTTRAUMATIC STRESS DISORDER. TREATMENT AND REHABILITATION. Psychogenic diseases are a large and clinically varied group of diseases resulting from an effect of acute or long-term psychic traumas, which manifest themselves by both mental and somatoneurological disorders and, as a rule, are reversible. Psychogenic diseases are caused by a psychic trauma, i.e. some events which affect significant aspects of existence of the human being and result in deep psychological feelings. These may be subjectively significant events, i.e. those which are pathogenic for the majority of people. Besides, the psyche may be traumatized by conventionally pathogenic events, which cause feelings in an individual because of his peculiar hierarchy of values. Unfavorable psychogenic effects on the human being cause stress in him, i.e. a nonspecific reaction at the physiological, psychological and behavioural levels. Stress may exert some positive, mobilizing influence, but may result in disorganization of the organism activity. The stress, which exerts a negative influence and causes various disturbances and even diseases, is termed distress. Classification of neurotic disorders I.
    [Show full text]
  • Practice Guidelines for the Assessment and Diagnosis Of
    Practice Guidelines forthe Assessment and Diagnosis of Mental Health Problems in Adults with Intellectual Disability Practice Guidelines In the last decade the professional knowledge concerning the problems for the Assessment of mental health among persons with intellectual disability has grown significantly. Behavioural and psychiatric disorders can cause serious and Diagnosis of obstacles to individual’s social integration. Clinical experience and research show that the existing diagnostic Mental Health systems of DSM-IV and ICD-10 are not fully compatible when making a psychiatric diagnosis in people with intellectual disability. This may be Problems in Adults one of the reasons why the evidence-based knowledge on the assessment and diagnosis of mental health problems in people with intellectual with Intellectual disability is still scarce. Disability This is the reason for the European Association for Mental Health in Mental Retardation (MH-MR) supporting the current project to Shoumitro Deb, produce a series of Practice Guidelines for those working with people Tim Matthews, with intellectual disability, to encourage and promote evidence-based Geraldine Holt & Nick Bouras practice. This is the first publication of the series. ISBN 1-84196-064-0 Practice Guidelines for the Assessment and Diagnosis of Mental Health Problems in Adults with Intellectual Disability Practice Guidelines for the Assessment and Diagnosis of Mental Health Problems in Adults with Intellectual Disability Shoumitro Deb, Tim Matthews, Geraldine Holt & Nick Bouras Practice Guidelines for the Assessment and Diagnosis of Mental Health Problems in Adults with Intellectual Disability © Shoumitro Deb, Tim Matthews, Geraldine Holt & Nick Bouras Shoumitro Deb, Tim Matthews, Geraldine Holt & Nick Bouras have asserted their rights under the Copyright, Designs and Patent Act 1988 to be recognised as the authors of this work.
    [Show full text]
  • ACGME Psychiatry Milestones
    Psychiatry Milestones The Accreditation Council for Graduate Medical Education Implementation Date: July 1, 2021 Second Revision: March 2020 First Revision: November 2013 ©2020 Accreditation Council for Graduate Medical Education (ACGME) All rights reserved except the copyright owners grant third parties the right to use the Psychiatry Milestones on a non-exclusive basis for educational purposes. Psychiatry Milestones The Milestones are designed only for use in evaluation of residents in the context of their participation in ACGME-accredited residency or fellowship programs. The Milestones provide a framework for the assessment of the development of the resident in key dimensions of the elements of physician competence in a specialty or subspecialty. They neither represent the entirety of the dimensions of the six domains of physician competence, nor are they designed to be relevant in any other context. ©2020 Accreditation Council for Graduate Medical Education (ACGME) All rights reserved except the copyright owners grant third parties the right to use the Psychiatry Milestones on a non-exclusive basis for educational purposes. ii Psychiatry Milestones Work Group Elie Aoun, MD Laura Edgar, EdD, CAE Jeff Aronowitz, DO Lillian Joy Houston, MD, FAPA Adrienne Bentman, MD Furhut Janssen, DO Lynneice Bowen, MD George Keepers, MD Brittany Campbell Mark Kinzie, MD, PhD Deborah Cowley, MD Matthew Macaluso, DO Sandra DeJong, MD, MSc Patcho Santiago, MD, MPH The ACGME would like to thank the following organizations for their continued support in the development of the Milestones: American Association of Directors of Psychiatric Residency Training American Board of Psychiatry and Neurology American College of Osteopathic Neurologists and Psychiatrists American Osteopathic Board of Psychiatry and Neurology ACGME Review Committee for Psychiatry ©2020 Accreditation Council for Graduate Medical Education (ACGME) All rights reserved except the copyright owners grant third parties the right to use the Psychiatry Milestones on a non-exclusive basis for educational purposes.
    [Show full text]
  • American Psychiatric Association the Principles of Medical Ethics
    American Psychiatric Association The Principles of Medical Ethics With Annotations Especially Applicable to Psychiatry 2013 Edition Copyright © 2010 American Psychiatric Association ALL RIGHTS RESERVED Manufactured in the United States of America 08 07 06 3 2 1 The Principles of Medical Ethics 2013 Edition (Previous editions 1973, 1978, 1981, 1984, 1985, 1989, 1992, 1993, 1995, 1995 Revised, 1998, 2001, 2001 Revised, 2006, 2008, 2009. 2009 Revised, and 2010 American Psychiatric Association 1000 Wilson Boulevard #1825 Arlington, VA 22209 THE PRINCIPLES OF MEDICAL ETHICS With Annotations Especially Applicable to Psychiatry 2013 Edition In 1973, the American Psychiatric Association (APA) published the first edition of The Principles of Medical Ethics with Annotations Especially Applicable to Psychiatry. Subsequently, revisions were published as the APA Board of Trustees and the APA Assembly approved additional annotations. In July of 1980, the American Medical Association (AMA) approved a new version of the Principles of Medical Ethics (the first revision since 1957), and the APA Ethics Committee1 incorporated many of its annotations into the new Principles, which resulted in the 1981 edition and subsequent revisions. This version includes changes to the Principles approved by the AMA in 2001. Foreword ALL PHYSICIANS should practice in accordance with the medical code of ethics set forth in the Principles of Medical Ethics of the American Medical Association. An up-to-date expression and elaboration of these statements is found in the Opinions and Reports of the Council on Ethical and Judicial Affairs of the American Medical Association.2 Psychiatrists are strongly advised to 3 be familiar with these documents. However, these general guidelines have sometimes been difficult to interpret for psychiatry, so further annotations to the basic principles are offered in this document.
    [Show full text]
  • Bioethical Differences Between Drug Addiction Treatment Professionals Inside and Outside the Russian Federation Mendelevich
    Bioethical differences between drug addiction treatment professionals inside and outside the Russian Federation Mendelevich Mendelevich Harm Reduction Journal 2011, 8:15 http://www.harmreductionjournal.com/content/8/1/15 (10 June 2011) Mendelevich Harm Reduction Journal 2011, 8:15 http://www.harmreductionjournal.com/content/8/1/15 RESEARCH Open Access Bioethical differences between drug addiction treatment professionals inside and outside the Russian Federation Vladimir D Mendelevich Abstract This article provides an overview of a sociological study of the views of 338 drug addiction treatment professionals. A comparison is drawn between the bioethical approaches of Russian and foreign experts from 18 countries. It is concluded that the bioethical priorities of Russian and foreign experts differ significantly. Differences involve attitudes toward confidentiality, informed consent, compulsory treatment, opioid agonist therapy, mandatory testing of students for psychoactive substances, the prevention of mental patients from having children, harm reduction programs (needle and syringe exchange), euthanasia, and abortion. It is proposed that the cardinal dissimilarity between models for providing drug treatment in the Russian Federation versus the majority of the countries of the world stems from differing bioethical attitudes among drug addiction treatment experts. Introduction deontological norms [6,10]. Although there have been Russian and international narcology (addiction medi- calls for adherence to the principles of medical ethics, cine) began to develop along divergent paths during the the procedures put into practicecontinuetobeincom- second half of the twentieth century. Indeed, Russian patible with these principles. Drug addicts still have narcology has ceased to be a part of international nar- even fewer patient rights than the mentally ill.
    [Show full text]
  • Early Identification of Psychosis a Primer
    Early Identification of Psychosis A Primer Mental Health Evaluation & Community Consultation Unit TABLE OF CONTENTS Introduction...............................................................................................................3 Psychosis and Early Intervention........................................................................4 Why is Early Intervention Needed?...................................................................5 Risk and Onset..........................................................................................................6 Course of First-Episode Psychosis 1. Prodrome........................................................................................................7 2. Acute Phase....................................................................................................8 3. Recovery Phase..............................................................................................9 Summary of First-Episode Psychosis...............................................................11 Tips for Helpers......................................................................................................12 More Resources......................................................................................................15 Acknowledgements...............................................................................................16 2 INTRODUCTION Psychosis is a condition characterized by loss of contact with reality and may involve severe disturbances in perception, cognition, behavior,
    [Show full text]
  • Young Mania Rating Scale (YMRS)
    PATIENT EDUCATION TOOLS Young Mania Rating Scale (YMRS) OVERVIEW The Young Mania Rating Scale (YMRS) is one of the most frequently utilized rating scales to assess manic symptoms. The scale has 11 items and is based on the patient’s subjective report of his or her clinical condition over the previous 48 hours. Additional information is based upon clinical observations made during the course of the clinical interview. The items are selected based upon published descriptions of the core symptoms of mania. The YMRS follows the style of the Hamilton Rating Scale for Depression (HAM-D) with each item given a severity rating. There are four items that are graded on a 0 to 8 scale (irritability, speech, thought content, and disruptive/aggressive behavior), while the remaining seven items are graded on a 0 to 4 scale. These four items are given twice the weight of the others to compensate for poor cooperation from severely ill patients. There are well described anchor points for each grade of severity. The authors encourage the use of whole or half point ratings once experience with the scale is acquired. Typical YMRS baseline scores can vary a lot. They depend on the patients’ clinical features such as mania (YMRS = 12), depression (YMRS = 3), or euthymia (YMRS = 2). Sometimes a clinical study entry requirement of YMRS > 20 generates a mean YMRS baseline of about 30. Strengths of the YMRS include its brevity, widely accepted use, and ease of administration. The usefulness of the scale is limited in populations with diagnoses other than mania. The YMRS is a rating scale used to evaluate manic symptoms at baseline and over time in individuals with mania.
    [Show full text]